scispace - formally typeset
Search or ask a question

Why are natural products important in anti cancer research? 


Best insight from top research papers

Natural products are important in anti-cancer research due to their diverse chemical structures and unique biofunctionality, which make them valuable sources of new therapeutic drugs . They have shown positive trends in preclinical research and have prompted numerous innovative strategies to combat cancer . More than 60% of contemporary anticancer drugs have originated from natural sources . Plant-derived anticancer drugs, in particular, have played a significant role in producing effective agents against cancer . These compounds have demonstrated potent inhibitory effects on cancer cell lines and are therefore in high demand . Natural products offer advantages such as high molecular diversity, novel biofunctionality, and superior efficacy and safety . They also provide potential for the development of targeted treatment therapies . Overall, natural products offer a promising avenue for the discovery and development of new and effective anticancer agents .

Answers from top 5 papers

More filters
Papers (5)Insight
Natural products are important in anti-cancer research because they are readily available, have shown potent anti-cancer activity, and have played a significant role in the treatment of various types of cancer.
Natural products are important in anti-cancer research because they provide attractive therapeutic agents with diverse chemical properties, and more than 60% of contemporary anticancer drugs have originated from natural sources.
Natural products are important in anti-cancer research because they provide a significant source of new therapeutic drugs with high molecular diversity and unique molecular properties.
Natural products are important in anti-cancer research because they have been a valuable resource for the discovery of anti-cancer drugs and can provide cost-effective therapeutics for cancer treatment.

Related Questions

How can the anticancer effects of plants be used to treat cancer?4 answersPlant-derived compounds have shown potential in treating cancer by targeting multiple cancer hallmarks and inhibiting tumor growth. These compounds, such as vincristine, taxol, and resveratrol, have been used in clinical settings for cancer treatment. Medicinal plants contain bioactive compounds that have therapeutic properties and can be used as an alternative to synthetic medicine. Studies have shown that plant extracts and their active principles, such as those from Alpina galaga, Urtica dioica, and Nigella sativa, have exhibited anticancer activities by reducing cell proliferation, inducing programmed cell death, and triggering cell-cycle arrest. Natural remedies, including herbs like acacia, basil, and garlic, have also been found to have promising anticancer effects. The use of plant-derived natural products provides a diverse range of chemical structures and low toxicity, making them a potential source for the development of new and more effective anticancer therapies.
What is the role of plant-derived compounds in anticancer drug discovery?5 answersPlant-derived compounds play a significant role in anticancer drug discovery. These compounds, such as flavonoids, polyphenols, and bioactive phytocompounds, have demonstrated antioxidant, anti-inflammatory, and anticancer properties. They can scavenge free radicals, prevent inflammation, and inhibit the formation of tumors. Plant-derived compounds have been used in combination therapies with other anticancer agents, leading to effective management of various malignancies. Additionally, the incorporation of plant-derived compounds into nanoparticles or antibodies can improve their bioavailability and enhance their therapeutic effects. These compounds have also been shown to modulate various signaling pathways involved in cancer development and progression, such as P13K/AKT, NF-κB, JNK, and ERK. Overall, plant-derived compounds offer potential advantages in terms of selectivity, efficacy, and reduced off-target toxicities, making them valuable in the discovery and development of anticancer drugs.
What are the cancer chemo preventive effects of certain herbal medicines?5 answersCertain herbal medicines have shown cancer chemo preventive effects. Studies have reported the beneficial effects of herbal medicines on the survival, immune modulation, and quality of life of cancer patients when used in combination with conventional therapeutics. Natural compounds in herbal medicines have been found to inhibit tumor formation and are well tolerated by patients at high doses. Herbal extracts, such as SH003, have been effective in treating lung and respiratory diseases and reducing symptoms induced by particulate matter. Herbal therapeutics have also shown potential in preventing and treating ROS-induced cancer through their chemopreventive and antioxidant properties. Additionally, natural products and their combinations with chemotherapeutics have been found to mediate anticancer effects by modulating signaling pathways involved in apoptosis, cellular proliferation, and immune response. The concomitant use of herbal medicines with chemotherapy has been demonstrated to be beneficial in multiple malignant tumors, improving the quality of life of patients and alleviating side effects.
Are herbal medicines effective chemopreventive agents for cancer?5 answersHerbal medicines have shown potential as effective chemopreventive agents for cancer. Phytochemicals derived from plants have been found to influence cell proliferation, cell cycle regulation, and multiple signaling pathways involved in tumor initiation and progression. These compounds can strengthen the immune system and make cancer cells more susceptible to cell-damaging agents. Additionally, herbal products have been shown to modulate the immune system with low toxicity and decrease the side effects of conventional cancer therapy. Traditional Chinese medicine, including herbal medicine, has been used to control tumor growth, reduce suffering, and improve the quality of life for cancer patients. Research has focused on the immunomodulatory effects of herbal medicine, including its ability to stimulate the immune response and alter the tumor immune microenvironment. Overall, herbal medicines have shown promise as chemopreventive agents for cancer through their effects on cell signaling, immune modulation, and tumor microenvironment.
Which plant extracts have been shown to have anti-cancer activity?1 answersPlant extracts from the Lamiaceae family, including selected species, have shown potential anti-cancer activity against lung, breast, prostate, and colon cancer cells. These extracts contain phytochemicals that can modulate cancer-related molecular targets and support anti-tumor treatment. Additionally, various plant species have been found to possess potent anticancer compounds. In vitro studies have demonstrated the inhibition of cancer cell growth through DNA damage and activation of apoptosis-inducing enzymes by secondary metabolites in plant extracts. In vivo studies have also shown promising results in inhibiting cancer in animal models. Natural therapeutic agents derived from herbs have become important in the development of multi-treatment strategies for cancer therapy. These agents have shown potential anti-tumorigenic effects and have been studied extensively in animal cell culture, animal models, and preclinical trials. Plant-derived natural products have been widely used as anticancer agents, and their sources, extraction methods, mechanisms of action, clinical studies, and pharmaceutical formulations have been extensively discussed.
Are there any anti-cancer drugs derived from traditional medicine?5 answersYes, there are anti-cancer drugs derived from traditional medicine. Traditional Chinese medicine (TCM) has been found to have anti-cancer effects. TCM contains various biologically active compounds that have shown efficacy against lung cancer, such as flavonoids, alkaloids, terpenoids, and polyphenols. These compounds have been found to suppress tumor cell cycle, inhibit proliferation, induce apoptosis, promote autophagy, inhibit tumor cell invasion and metastasis, and enhance efficacy when combined with other treatments. TCM has also been found to regulate DNA methylation modification, which plays a role in tumor development, making it a potentially reliable epigenetic drug. The anti-cancer traditional Chinese medicine compositions mentioned in the abstracts have shown good treatment effects for cancers and have been stable in their curative effects.

See what other people are reading

What is the difference between polyclonal and monoclonal antibody?
5 answers
Polyclonal antibodies are heterogeneous antibodies produced by different B cell clones, recognizing various epitopes on an antigen, while monoclonal antibodies (mAbs) are homogeneous antibodies generated by identical B cell clones, targeting a specific antigen site. Monoclonal antibodies offer high specificity and targeted treatment, making them preferred over polyclonal antibodies in various diseases, including cancer. The development of mAbs has evolved from murine to chimeric or humanized forms to reduce immunogenicity and enhance efficacy. Monoclonal antibodies have revolutionized medicine, with about 20% of new drugs being therapeutic mAbs, particularly in oncology and immunology. Their applications extend to autoimmune diseases, malignancies, and diagnostic assays due to their high affinity and specificity.
Who do PTEN may be served as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma?
5 answers
PTEN mutation may serve as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma. Studies have shown that patients with low PTEN levels in their tumors exhibit higher levels of immunosuppressive factors like CXCL10, PD-L1, and PD-L2, leading to worse outcomes when treated with immunotherapy. Additionally, PTEN loss in lung squamous cell carcinoma (LUSC) creates an immunosuppressive tumor microenvironment by promoting the infiltration of regulatory T cells (Tregs) and expressing higher levels of immunosuppressive genes, resulting in resistance to anti-PD-1 therapy. This resistance can be reversed therapeutically by targeting the immunosuppressive microenvironment through treatments like TLR agonists and anti-TGF-β antibodies, leading to tumor rejection and immunological memory.
What is gut microbiome composition ?
5 answers
The gut microbiome refers to the collection of microorganisms like bacteria, archaea, viruses, and fungi residing in the gut and their genetic information. It plays a crucial role in influencing various aspects of human health, including immune function, metabolism, detoxification, and even behavior. The composition of the gut microbiota is closely linked to factors such as diet, geographical location, antibiotic use, exercise, and different disease states. Research suggests that the gut microbiota can serve as a valuable biomarker for metabolic health, with implications for conditions like obesity, cardiometabolic events, gastrointestinal issues, and mental diseases. Additionally, the gut microbiota can be influenced by dietary patterns, as seen in studies exploring the impact of diet quality scores on gut microbiota composition in pregnant women.
How does TIM-3's modulation affect the efficacy of cancer immunotherapy in renal cell carcinoma (RCC)?
5 answers
Modulation of TIM-3 impacts cancer immunotherapy efficacy in renal cell carcinoma (RCC) by regulating immune responses. TIM-3, a negative regulator of immunity, interacts with dendritic cells (DCs) and T cells, influencing T cell activation and trogocytosis. In RCC, TIM-3 blockade disrupts trogocytosis of activated tumor-specific CD8+ T cells, enhancing antitumor immunity and reducing tumor burden. Additionally, TIM-3 and PD-1 blockades synergize to inhibit trogocytosis, promoting T cell survival and tumor control. These findings underscore TIM-3's crucial role in modulating immune responses in RCC and highlight its potential as a target for enhancing cancer immunotherapy efficacy in this context.
Drugs or immune targeted therapy for TGF-β ?
5 answers
Targeted therapies for TGF-β, a multifunctional cytokine with roles in both cancer progression and immune suppression, are crucial in cancer treatment. Various approaches have been developed, including small molecule inhibitors, monoclonal antibodies, ligand traps, and vaccines, to block TGF-β signaling and inhibit tumorigenesis and metastasis. Notably, drugs like Vactosertib, Bintrafusp alfa, AVID200, and Luspatercept show promise in targeting the TGF-β pathway effectively and safely, with demonstrated efficacy against different cancer types. Combining anti-TGF-β agents with immune checkpoint inhibitors can enhance immunomodulatory therapeutic approaches, potentially expanding the benefits of immune checkpoint inhibition to more cancer patients. These targeted therapies aim to minimize toxicity while maximizing specificity in inhibiting TGF-β signaling, offering novel treatment options for cancer patients.
What types of nanoparticles have shown promise in treating colorectal cancer?
10 answers
Nanoparticles have emerged as a significant advancement in the treatment of colorectal cancer (CRC), offering innovative approaches to overcome the limitations of conventional therapies. Various types of nanoparticles have been identified and explored for their potential in CRC treatment, each with unique properties and mechanisms of action. Liposomes, niosomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles are among the miniaturized nanocarriers that have been employed for both passive and active targeting in CRC, showing promise in enhancing diagnosis, treatment, and theranostic applications. Magneto-fluorescent NANO3 nanoparticles, specifically designed for combinatory anti-tumoral nanotherapy, have demonstrated significant cytotoxicity against CRC cells, especially when modified with targeting agents such as an anti-CA IX acetazolamide derivative and Cetuximab. The exploration of nanomaterials like carbon nanotubes, dendrimers, silica nanoparticles, gold nanoparticles, and metal-organic frameworks has also been highlighted for their potential in targeted anticancer drug delivery and diagnostic purposes. Photodynamic therapy using porphysome nanoparticles represents another innovative approach, offering outpatient neoadjuvant treatment possibilities for CRC. The application of nanotechnology has been further emphasized for its role in overcoming therapeutic resistance and preventing metastasis, with nanomaterials enhancing drug mobility, treatment efficacy, and reducing systemic toxicity. Nanoparticles have also been utilized to reverse the immunosuppressive tumor microenvironment (TME), thereby potentiating the effect of immunotherapeutic agents. Diatomite nanoparticles (DNPs) have been introduced as biocompatible nanocarriers capable of delivering chemotherapeutic agents against specific targets while reducing off-target effects. The review of nanocarrier-based strategies for CRC treatment has underscored the necessity for effective and targeted options, with several nanoparticles recommended for clinical purposes. Plasmonic (gold) nanoparticles have been identified for their dual therapeutic functionalities as photothermal therapy agents and radiosensitizers, offering a synergistic combination of radio- and phototherapies. Lastly, the use of polymeric nanoparticles, gold nanoparticles, liposomes, and solid lipid nanoparticles has been discussed for their efficacy in drug delivery systems specifically targeting CRC. These findings collectively underscore the diverse and promising role of nanoparticles in advancing the treatment of colorectal cancer, highlighting the potential for more effective, targeted, and less toxic therapeutic options.
What is the specific molecular target of chloroquine in Haemonchus contortus that leads to the inhibition of toxicity?
5 answers
Chloroquine (CQ) inhibits the activity of CYP2D6, an essential enzyme for primaquine (PQ) pharmacologic activity in Haemonchus contortus. This inhibition affects the metabolism of PQ, shifting metabolite pathway balances to reduce toxicity while maintaining efficacy against the parasite. Additionally, CQ suppresses CYP2D6-mediated hydroxylation and the formation of certain metabolites, such as glucuronides, in a dose-dependent manner. The complex interactions between CQ and PQ metabolism suggest a mechanism where CQ alters metabolite pathways to retain efficacy and reduce toxic metabolites, potentially by affecting transport or distribution of metabolites in a way that mitigates toxicity while preserving anti-malarial activity.
What are the benefits of trial transcripts?
5 answers
Trial transcripts offer various advantages in different contexts. They can enhance precision oncology trials by integrating transcriptomics to predict patient responses to targeted therapies. Additionally, real-world data (RWD) integrated with transcriptomics can provide insights into disease pathways and clinical outcomes, aiding in personalized medicine. Moreover, trial transcripts can improve the accuracy of audio data recognition, facilitating the processing of trial information for multiple terminals. Overall, trial transcripts play a crucial role in advancing medical research, optimizing patient selection for treatments, and improving the efficiency of clinical trials through data integration and analysis.
Dose of Camptothecin for treatment of colorectal cancer
5 answers
The effective dose of a camptothecin derivative for the treatment of colorectal cancer is approximately 0.05 to 1 mg/kg body weight/day when dissolved in a non-aqueous solvent, as suggested in a study focusing on an oral pharmaceutical composition. Camptothecins, including irinotecan, are potent topoisomerase I inhibitors used in colorectal cancer treatment, but their high toxicity and administration challenges have been noted. Research has explored the upregulation of DNA damage response-related molecules and apoptosis proteins by a novel topoisomerase inhibitor, PCC0208037, showing promising anti-tumor efficacy in colorectal cancer cells and xenograft models, potentially offering a comparative advantage over standard treatments like irinotecan. Additionally, combining topoisomerase inhibitors like camptothecin with immune-checkpoint inhibitors has been suggested to enhance treatment outcomes in colon cancer by modulating immunoregulatory responses.
How immunocal impact infant cancer?
5 answers
Immunotherapy has revolutionized pediatric cancer treatment, offering promising outcomes for previously challenging cases. Monoclonal antibodies, bispecific antibodies, and cellular therapies like CAR T-cells and NK cells have shown significant clinical responses in pediatric cancers, including neuroblastoma and leukemia. Immunotherapies have demonstrated impressive antitumor effects in high-risk neuroblastoma and acute B-cell lymphoblastic leukemia, enhancing survival rates. Despite initial disappointments in pediatric sarcomas, ongoing trials suggest that immunotherapy will eventually improve outcomes for high-risk malignancies, broadening the therapeutic arsenal against pediatric cancers. The specificity for cancer cells, in vivo persistence, and potency against refractory diseases make immunotherapies a valuable addition to conventional treatments, potentially reducing the chemotherapeutic burden while increasing cure rates in pediatric cancer.
How does plasma protein binding effect the distribution volume?
5 answers
Plasma protein binding significantly impacts the distribution volume of a drug. The extent of protein binding in plasma or tissues plays a crucial role in controlling the volume of distribution, which in turn affects both hepatic and renal clearance. The volume of distribution (V) is determined by the fraction unbound in plasma (fu), the fraction unbound in tissue (fuT), the volume of tissue (VT), and the volume of plasma (VP). Additionally, modulation of plasma protein binding can be part of a viable strategy in drug discovery to optimize the effective half-life of drug candidates in humans, especially for acidic molecules. Understanding the relationship between plasma protein binding and drug distribution is essential for pharmacokinetic optimization and predicting the volume of distribution in humans.